Prasinezumab · PARAISO
The sponsor provides a current Phase 3 PARAISO overview linked to this NCT. Earlier PADOVA and PASADENA findings do not answer PARAISO's motor-progression outcome. prasinezumab — phase 3 study in Parkinson's Disease. NCT07174310 lists Time to Confirmed Motor Progression Event on Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score as a primary outcome (Up to at least Week 104). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2029-06-30 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Phase 3 Parkinson's monitor — date unconfirmed
Potential outcome market
Will prasinezumab meet the prespecified primary endpoint in NCT07174310 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.